[Skip to Content]
[Skip to Content Landing]
Views 640
Citations 0
Research Letter
August 8, 2019

Women’s Representation Among Lead Investigators of Clinical Trials in Oncology

Author Affiliations
  • 1The University of Texas MD Anderson Cancer Center, Houston
  • 2Baylor College of Medicine, Houston, Texas
  • 3The University of Texas Health Science Center McGovern Medical School, Houston
  • 4The University of Tennessee Health Science Center College of Medicine, Memphis
JAMA Oncol. Published online August 8, 2019. doi:10.1001/jamaoncol.2019.2196

With increasing representation of women in medicine, recent efforts have attempted to determine whether women are adequately represented among leaders of academic medicine and published studies.1-3 We studied the representation of female lead authors for oncologic phase 3 randomized clinical trials (RCTs) because trial leadership affects promotion and tenure, prominence in the field, and access to subsequent funding opportunities. We quantified the proportion of RCTs led by women over time and determined factors associated with female corresponding authorship (FCA) among oncologic RCTs.

×